Loading...
XSHE000078
Market cap875mUSD
Jan 13, Last price  
2.44CNY
1D
0.83%
1Q
0.41%
Jan 2017
-61.27%
Name

Shenzhen Neptunus Bioengineering Co. Ltd

Chart & Performance

D1W1MN
XSHE:000078 chart
P/E
—
P/S
0.18
EPS
—
Div Yield, %
8.63%
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
-1.04%
Revenues
36.42b
-3.74%
2,321,947,0952,657,991,8862,690,784,5002,495,001,6672,211,799,5302,710,042,8673,999,052,3535,305,028,9486,418,021,7067,993,433,9719,802,350,83111,117,734,98513,605,921,66724,939,637,65338,380,907,26241,492,703,94540,022,495,40941,053,584,12837,834,858,74536,418,770,306
Net income
0k
22,070,214042,470,24838,680,46024,303,60414,158,96746,668,56352,528,35959,066,952117,047,96323,791,540474,732,125418,395,707639,190,547448,205,940514,901,7720257,867,59600
CFO
0k
035,824,61654,041,40950,586,344205,386,434206,344,07440,956,744000090,507,1100002,268,621,9341,650,554,959866,120,63400
Dividend
Jul 16, 20190.02 CNY/sh
Earnings
Jun 13, 2025

Profile

Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.
URL
https://www.neptunusbio.com/
IPO date
Dec 18, 1998
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
36,418,770
-3.74%
37,834,859
-7.84%
Cost of revenue
34,671,020
36,011,701
Unusual Expense (Income)
NOPBT
1,747,751
1,823,158
NOPBT Margin
4.80%
4.82%
Operating Taxes
260,559
138,972
Tax Rate
14.91%
7.62%
NOPAT
1,487,192
1,684,186
Net income
Dividends
(553,834)
Dividend yield
6.70%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
10,832,202
11,615,508
Long-term debt
439,977
511,928
Deferred revenue
22,872
26,487
Other long-term liabilities
2,668
7,481
Net debt
7,426,959
8,620,368
Cash flow
Cash from operating activities
CAPEX
(104,075)
(94,318)
Cash from investing activities
(140,425)
Cash from financing activities
724,842
322,103
FCF
3,318,265
1,539,364
Balance
Cash
3,674,814
3,318,553
Long term investments
170,405
188,514
Excess cash
2,024,281
1,615,325
Stockholders' equity
2,234,739
4,170,310
Invested Capital
13,371,102
16,281,738
ROIC
10.03%
10.11%
ROCE
11.34%
10.18%
EV
Common stock shares outstanding
2,631,123
2,631,123
Price
3.14
-5.42%
3.32
-5.95%
Market cap
8,261,727
-5.42%
8,735,329
-5.95%
EV
17,178,327
18,873,753
EBITDA
2,045,304
2,099,313
EV/EBITDA
8.40
8.99
Interest
992,413
930,859
Interest/NOPBT
56.78%
51.06%